found that CD90(+) cells possessed an increased capacity of tumorigenicity in vivo compared with CD90(-) cells, and the expression level of CD90(+) cells was positively correlated with the tumorigenicity of GC cells in vivo. This evidence concerns the gene THY1 and gastric cancer.